Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
1. CNTB terminated its ADR program, listing directly on Nasdaq. 2. Listing on Nasdaq aims to enhance visibility and attract U.S. investors. 3. The company focuses on clinical trials for rademikibart, targeting inflammatory diseases. 4. rademikibart may provide a promising treatment for asthma and COPD. 5. Forward-looking statements indicate potential benefits amid associated risks.